Every approved cancer drug ships with a public combination-readiness data pack
Require that approved cancer drugs come with a standard set of data (blood levels, drug interactions, toxicity profile) so anyone can design a safe combination trial without asking the company.
Combination trial designers need pharmacokinetic profiles, metabolic pathways, QT effects, myelosuppression kinetics and immunogenicity data that sit in confidential regulatory dossiers. A standardised, machine-readable 'combination-readiness' annex published at approval would let academics and other companies design combination studies and predict overlapping toxicity without bilateral negotiation.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA patent pool for combination method-of-use claims
Shares A standard cross-company combination agreement that takes weeks, not years, to sign, Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaRequire every oncology candidate to publish how much reaches the brain
Shares DrugBank & ChEMBL, FDA Oncology Approvals (OCE) & Novel Drug Approvals.
- IdeaA shared compound library that rare cancer researchers can actually use
Shares DrugBank & ChEMBL, Secrecy and intellectual property block collaboration.
- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA legal right to obtain marketed cancer drugs at cost for combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaAn open engine that ranks every drug pair by predicted synergy before anyone runs a trial
- IdeaA publicly held library of investigational drugs available for academic combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.